Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 76

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 76
---
 to the approval by the Company’s stockholders of the Amended 2021 Plan. Option awards are granted with an exercise price equal to the closing price of the Company's common stock as of the grant date. Options and awards granted have a ten year contractual term. Options and awards granted to employees, consultants and advisors generally vest in four equivalent annual installments, starting on the first anniversary of the grant's date. Options and awards granted to the directors generally vest over a one year term.Employee Stock Purchase PlanThe Company has adopted the Supernus Pharmaceuticals, Inc. 2012 Employee Stock Purchase Plan (as amended to date, the ESPP). The ESPP allows eligible employees the opportunity to acquire shares of the Company's common stock at periodic intervals through accumulated payroll deductions. These deductions are applied at the semi-annual purchase dates of June 30 and December 31 to purchase shares of common stock from the Company at a discount. Eligible employees may purchase shares at the lower of 85% of the fair market value at either the first day of the purchase period or the fair market value at the end of the purchase period. The ESPP provides for the issuance of up to 1,700,000 shares of the Company's common stock. The Company records compensation expense related to its ESPP.Share-based compensation expense

117

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)9. Share-Based Payments (Continued)

Share-based compensation expense is as follows (dollars in thousands): Year Ended December 31, 202420232022Research and development$5,148 $4,743 $2,922 Selling, general and administrative22,607 22,016 14,646 Total$27,755 $26,759 $17,568 Stock Option The following table summarizes stock option activities:Number ofOptionsWeightedAverageExercise Price(per share)WeightedAverageRemainingContractualTerm (in years)AggregateIntrinsic Value(in thousands)Outstanding, December 31, 20225,797,569 $26.99 6.1$53,650 Granted1,204,643 $37.78 Exercised(258,154)$16.70 Forfeited(160,236)$33.48 Outstanding, December 31, 20236,583,822 $29.20 5.9$23,668 Granted